You just read:

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

News provided by

GlaxoSmithKline plc

Sep 28, 2019, 10:31 ET